Title |
Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry
|
---|---|
Published in |
Clinical Rheumatology, July 2017
|
DOI | 10.1007/s10067-017-3742-2 |
Pubmed ID | |
Authors |
Leslie R. Harrold, Ani John, Jennie Best, Steve Zlotnick, Chitra Karki, YouFu Li, Jeffrey D. Greenberg, Joel M. Kremer |
Abstract |
To evaluate the impact of rituximab on patient-reported outcomes (PROs) in a US-based observational cohort of patients with rheumatoid arthritis (RA). Patients with active RA, prior exposure to ≥1 tumor necrosis factor inhibitor (TNFi) and who newly initiated rituximab were identified. Changes in PROs were assessed 1 year after rituximab initiation. PRO measures included Clinical Disease Activity Index (CDAI); patient global disease activity, pain and fatigue (visual analog score; 0-100); morning stiffness (hours); modified Health Assessment Questionnaire (mHAQ; 0-3); and EuroQoL EQ-5D. Of the 667 patients who newly initiated rituximab, baseline PRO and clinical measures indicated that patients were substantially impacted by their RA disease and quality of life; 54% of patients had high disease activity. One year after rituximab initiation, 49.0, 47.1, 49.8, and 23.2% of patients reported clinically meaningful improvements in patient global, pain, fatigue, and mHAQ, respectively. Morning stiffness and EuroQol EQ-5D domains improved in 48 and 19-32% of patients, respectively. These real-world registry data demonstrated that patients with long-standing, refractory RA experienced improvements in PROs 1 year after initiating rituximab. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 27 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 4 | 15% |
Other | 3 | 11% |
Student > Doctoral Student | 3 | 11% |
Student > Master | 3 | 11% |
Researcher | 3 | 11% |
Other | 4 | 15% |
Unknown | 7 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 12 | 44% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 15% |
Nursing and Health Professions | 1 | 4% |
Biochemistry, Genetics and Molecular Biology | 1 | 4% |
Social Sciences | 1 | 4% |
Other | 1 | 4% |
Unknown | 7 | 26% |